Jt. Thx for posting that link Sold my small position in MDGL as soon as I saw the VKTX data . Doubt if MDGL really pursues the He FH market as their drug only lowered LDL by around 21%
I tend to think that the R-It data really crimps the potential for extra LDL lowering drugs ...ESPR ,MDGL etc .... and really shifts the focus away from only LDL . For the few Cardiologists I know ... it’s all about MOA at present .... how is Vascepa actually working Kiwi